700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|A3 Pharma Counselling Ltd, UK|
|Keynote: J Clin Trials|
|More clinically relevant outcome measures are greatly needed to allow physicians, health authorities, healthcare providers and patients to make robust therapeutic choices. 21st Century therapeutic decisions need to into account many factors such; increasing complexity of drugs, personalised medicine, and the demands of Healthcare providers for proof of cost effectiveness, the impact on the quality of life, and patient reported outcomes. Rapid scientific advances are leading to the development of new drugs that are usually more expensive, thus increasing the pressure on budgets and demands for more evidence based medicine. Hence, the increasing the need for more clinically relevant outcome measures to assist in choosing the right drugs. These outcome measure should take into account; the impact on the natural history of cancer and other conditions, and the burden of drugs on patient safety and quality of life. Clinical trials data are the basis for therapeutic decisions. However, some outcome measures do not provide the robust basis to make these decisions in cancer, time to clinical progression, MRI progression, surrogate marker progression are analysed separately. No collective impact on the natural history of cancer is measured. The data collected after progression, is not usually presented. Safety data are reported as an absolute list or summary with the number of patients with a specific AE. No identification patients who experience more than one AE contemporaneously, consecutively or the combination of incidence and severity and their impact on patients. I will present a new outcome measure utilising collected data that aims to help these needs.|
Ayad Abdul-Ahad is a Physician specialised in Oncology, Immunology and Haematology. He is trained in various teaching hospitals in the United Kingdom. He has spent the last 25 years in drug development and medical affairs. He has built and led teams across the Pharmaceutical and Biotechnology industries in the US and Europe that managed the clinical development and medical affairs for several drugs in oncology, neurology, pain, and immunology.
|PDF | HTML|